In a groundbreaking study, researchers have unveiled a critical protein, CFAP20, that acts as a traffic controller on the DNA railway. This discovery, published in the journal Nature, sheds light on how cells manage the complex process of DNA replication and transcription, potentially opening new avenues for cancer research and treatment.
DNA, often likened to a bustling railway system, consists of tracks made from four building blocks known as base pairs. Two types of molecular “trains” operate on these tracks: one responsible for copying DNA, known as replication, and the other for reading DNA, termed transcription. These trains, scientifically referred to as polymerases, travel at remarkable speeds of one to two thousand base pairs per minute, as explained by Professor Martijn Luijsterburg.
The Role of CFAP20 in Preventing Collisions
In the absence of CFAP20, the DNA railway faces potential chaos. The transcription train, which starts slowly, risks being rear-ended by the faster replication train. CFAP20 intervenes by accelerating the transcription process, preventing such collisions. Without this protein, the transcription train stalls, blocking the track and causing the replication train to crash into it.
‘The replication trains set off simultaneously at thousands of places in the DNA,’ says Luijsterburg. ‘Without CFAP20, half of them stop, whereas the other half become stressed and try to compensate by speeding up.’
This frantic speeding up, akin to hurriedly transcribing a book, results in errors and incomplete DNA copies. Such flawed copies can lead to cells dividing uncontrollably or following incorrect instructions, potentially resulting in cancer over time, warns researcher Sidrit Uruci.
Bridging Two Research Fields
The discovery of CFAP20’s function was made possible by the collaboration between two distinct research fields: replication, led by Uruci, and transcription, led by Luijsterburg. Historically, these fields operated in silos, with little interaction. However, by joining forces, the researchers were able to observe the interplay between replication and transcription, leading to this significant breakthrough.
Although CFAP20’s existence was known, its role within the cell nucleus had not been explored. This study marks the first time researchers have identified its crucial function as a traffic controller on the DNA railway.
Implications for Cancer Research and Treatment
While the discovery of CFAP20 as a traffic controller does not immediately translate into treatments, it lays the groundwork for future research. Luijsterburg emphasizes the importance of fundamental research, stating that such discoveries are essential for eventual clinical applications.
‘If we didn’t do fundamental research, we’d never make such discoveries. And then we’d never translate such insights to clinical practice and to patients,’ explains Luijsterburg.
For cancer biologists, the study provides additional insight into why cells may derail, leading to cancer. For drug developers, CFAP20 presents a potential target, as tumor cells appear to exploit this protein to divide more rapidly, despite compromising their DNA quality. Uruci suggests that targeting CFAP20 could be a future strategy for combating tumor cells.
Future Directions and Research Potential
The CFAP20 study opens new avenues for researchers, underscoring the value of exploring unknown genes and proteins. With the human genome consisting of approximately 20,000 genes, the vast majority of studies focus on a small fraction. Uruci highlights the potential for future discoveries, noting the importance of continuing to investigate the less-studied regions of the genome.
‘The human genome consists of 20,000 genes, but 99% of the studies are about the same 10%. Who knows what we might find in the future,’ says Uruci.
This research was supported by funding from an ERC Consolidator Grant and a Dutch Research Council Vici grant, demonstrating the critical role of financial backing in advancing scientific understanding.
